Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy
Avtorji:ID Vrankar, Martina (Avtor)
ID Stanič, Karmen (Avtor)
Datoteke:URL URL - Izvorni URL, za dostop obiščite https://content.sciendo.com/view/journals/raon/52/3/article-p281.xml
 
.pdf PDF - Predstavitvena datoteka, prenos (500,20 KB)
MD5: 258A46BB0F281F730951D019F87BF34B
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Povzetek:Standard treatment for patients with inoperable locally advanced non-small cell lung cancer (NSCLC) is concurrent chemoradiotherapy (CCRT). Five-year overall survival rates range between 15 and 25%, while long term survival data are rarely reported. Patients and methods A total of 102 patients with stage III NSCLC treated between September 2005 and November 2010 with induction chemotherapy and CCRT were included in this long term survival analysis. All patients were tested for PD-L1 status and expression of PD-L1 was correlated with overall survival (OS), progression free survival (PFS) and toxicities. Results The median OS of all patients was 24.8 months (95% CI 18.7 to 31.0) with 10 year-survival rate of 11.2%. The median OS of patients with PD-L1 expression was 12.1 months (95% CI 0.1 to 26.2), while in patients with negative or unknown PD-L1 status was significantly longer, 25.2 months (95% CI 18.9 to 31.6), p = 0.005. The median PFS of all patients was 16.4 months (95% CI 13.0 to 19.9). PFS of patients with PD-L1 expression was 10.1 months (95% CI 0.1 to 20.4) and in patients with negative or unknown PD-L1 status was 17.9 months (95% CI 14.2 to 21.7), p = 0.003. Conclusions 10-year overall survival of stage III NSCLC patients after CCRT is 11.2%. PFS and OS differ with regard to PD-L1 status and are significantly shorter for patients with PD-L1 expression. New treatment with check-point inhibitors combined with RT therefore seems reasonable strategy to improve these results.
Ključne besede:NSCLC, non-small cell lung cancer, locally advanced, immunotherapy, chemoradiotherapy
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Datum objave:01.09.2018
Kraj izida:Ljubljana
Založnik:Association of Radiology and Oncology
Leto izida:2018
Št. strani:str. 281-288, IV
Številčenje:Vol. 52, no. 3
Izvor:Ljubljana
PID:20.500.12556/DiRROS-19072 Novo okno
UDK:616.2
ISSN pri članku:1318-2099
DOI:10.1515/raon-2018-0009 Novo okno
COBISS.SI-ID:2855035 Novo okno
Avtorske pravice:by Authors
Datum objave v DiRROS:10.06.2024
Število ogledov:55
Število prenosov:42
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Radiology and oncology
Skrajšan naslov:Radiol. oncol.
Založnik:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 Novo okno

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:nedrobnocelični rak pljuč, lokalno napredovali rak pljuč, kemoradioterapija, imunoterapija


Nazaj